60 related articles for article (PubMed ID: 8668794)
21. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
[TBL] [Abstract][Full Text] [Related]
22. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
23. Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethra.
Pinkawa M; Holy R; Piroth MD; Klotz J; Pfister D; Heidenreich A; Eble MJ
Radiother Oncol; 2012 May; 103(2):247-51. PubMed ID: 22300607
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of high- and low-source strength (125)I prostate seed implants.
Narayana V; Troyer S; Evans V; Winfield RJ; Roberson PL; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):44-51. PubMed ID: 15629592
[TBL] [Abstract][Full Text] [Related]
25. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
26. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
[TBL] [Abstract][Full Text] [Related]
27. Anatomy-based inverse planning simulated annealing optimization in high-dose-rate prostate brachytherapy: significant dosimetric advantage over other optimization techniques.
Jacob D; Raben A; Sarkar A; Grimm J; Simpson L
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):820-7. PubMed ID: 18455325
[TBL] [Abstract][Full Text] [Related]
28. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants.
Yu Y; Waterman FM; Suntharalingam N; Schulsinger A
Int J Radiat Oncol Biol Phys; 1996 Feb; 34(3):717-25. PubMed ID: 8621297
[TBL] [Abstract][Full Text] [Related]
29. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
30. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
[TBL] [Abstract][Full Text] [Related]
31. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.
Nag S
Semin Urol Oncol; 2000 May; 18(2):133-6. PubMed ID: 10875454
[TBL] [Abstract][Full Text] [Related]
32. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
[TBL] [Abstract][Full Text] [Related]
33. Loading technique comparison in permanent 125I prostate implants.
Williams BV; Horton J; Lawyer A; Chapman J
Med Dosim; 1999; 24(4):273-7. PubMed ID: 10643736
[TBL] [Abstract][Full Text] [Related]
34. [Brachytherapy for prostate carcinoma].
Yorozu A
Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr; 65(2):87-91. PubMed ID: 15920966
[TBL] [Abstract][Full Text] [Related]
35. A new genetic algorithm technique in optimization of permanent 125I prostate implants.
Yang G; Reinstein LE; Pai S; Xu Z; Carroll DL
Med Phys; 1998 Dec; 25(12):2308-15. PubMed ID: 9874822
[TBL] [Abstract][Full Text] [Related]
36. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
[TBL] [Abstract][Full Text] [Related]
37. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
38. Dose homogeneity as a function of source activity in optimized I-125 prostate implant treatment plans.
D'Souza WD; Meyer RR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1120-30. PubMed ID: 11704337
[TBL] [Abstract][Full Text] [Related]
39. A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy.
Haworth A; Mears C; Betts JM; Reynolds HM; Tack G; Leo K; Williams S; Ebert MA
Phys Med Biol; 2016 Jan; 61(1):430-44. PubMed ID: 26675313
[TBL] [Abstract][Full Text] [Related]
40. Is there a preferred strength for regularly spaced 125I seeds in inverse-planned prostate implants?
Sloboda RS; Pedersen JE; Halperin R
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):234-44. PubMed ID: 12504058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
